Thu, 24th Jun 2021 08:07
(ShareCast News) - Allergy Therapeutics posted a rise in revenue for the year to the end of June but said it swung to a loss as it ramped up its spending on research and development. Revenue rose 12% from 2015 to £48.5m but the company reported a pre-tax loss of £12.1m versus a profit of £654,000 th
Read more(ShareCast News) - Numis reiterated a 'buy' rating and target price of 37p on Allergy Therapeutics on Monday after the company reported its full year results. Allergy reported a 19% increase in revenue at constant currency to £51.5m in the year ended 30 June as it grew market share in its main Europ
Read more(ShareCast News) - Specialty pharmaceutical company Allergy Therapeutics published a one-year follow up study of patients using Acarovac Plus on Friday, in the peer-review journal Immunotherapy. The AIM-traded firm's Acarovac Plus product was described as a microcrystalline tyrosine-adsorbed, house
Read more